GLP-1 Drugs and Kidney Disease
Host Julia Cartwright examines who benefits most from GLP-1 drugs for kidney protection in type 2 diabetes and chronic kidney disease. Drawing on the FLOW trial, Lancet meta-analyses, and Vanderbilt genetic research, she explores prescription gaps preventing high-risk patients from accessing these therapies and discusses emerging evidence for non-diabetic populations with obesity-related kidney disease. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.
4 episodes
Comments
0Be the first to comment
Sign up now and become a member of the GLP-1 Drugs and Kidney Disease community!